WEKO3
インデックスリンク
アイテム
Metformin Prevents and Reverses Inflammation in a Non-Diabetic Mouse Model of Nonalcoholic Steatohepatitis
http://hdl.handle.net/2297/32834
http://hdl.handle.net/2297/3283470d0faef-820b-4857-8d86-b0a5f05fc5dd
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
ME-PR-TAKAMURA-T-0043056.pdf (3.5 MB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2017-10-03 | |||||
| タイトル | ||||||
| タイトル | Metformin Prevents and Reverses Inflammation in a Non-Diabetic Mouse Model of Nonalcoholic Steatohepatitis | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 著者 |
Kita, Yuki
× Kita, Yuki× Takamura, Toshinari× Misu, Hirofumi× Ota, Tsuguhito× Kurita, Seiichiro× Takeshita, Yumie× Uno, Masafumi× Matsuzawa-Nagata, Naoto× Kato, Ken-ichiro× Ando, Hitoshi× Fujimura, Akio× Hayashi, Koji× Kimura, Toru× Ni, Yinhua× Otoda, Toshiki× Miyamoto, Ken-ichi× Zen, Yoh× Nakanuma, Yasuni× Kaneko, Shuichi |
|||||
| 書誌情報 |
PLoS ONE 巻 7, 号 9, p. e43056, 発行日 2012-09-18 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 1932-6203 | |||||
| DOI | ||||||
| 関連タイプ | isIdenticalTo | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1371/journal.pone.0043056 | |||||
| 出版者 | ||||||
| 出版者 | Public Library of Science | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Background: Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes. We examined the effects of metformin, commonly used to treat patients with type 2 diabetes, on liver pathology in a non-diabetic NASH mouse model. Methodology/Principal Findings: Eight-week-old C57BL/6 mice were fed a methionine- and choline-deficient plus high fat (MCD+HF) diet with or without 0.1% metformin for 8 weeks. Co-administration of metformin significantly decreased fasting plasma glucose levels, but did not affect glucose tolerance or peripheral insulin sensitivity. Metformin ameliorated MCD+HF diet-induced hepatic steatosis, inflammation, and fibrosis. Furthermore, metformin significantly reversed hepatic steatosis and inflammation when administered after the development of experimental NASH. Conclusions/Significance: These histological changes were accompanied by reduced hepatic triglyceride content, suppressed hepatic stellate cell activation, and the downregulation of genes involved in fatty acid metabolism, inflammation, and fibrogenesis. Metformin prevented and reversed steatosis and inflammation of NASH in an experimental non-diabetic model without affecting peripheral insulin resistance. © 2012 Kita et al. | |||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
